Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.

ABSTRACT:

Background

Interstitial lung disease/pneumonitis (ILD/pneumonitis) has been identified as a drug-related adverse event of special interest of trastuzumab deruxtecan (T-DXd), but there were a few reports of T-DXd-related ILD/pneumonitis in clinical practice.

Methods

Between May 25, 2020 (the launch of T-DXd in Japan) and February 24, 2022, there were 287 physician-reported potential ILD/pneumonitis cases from the Japanese post-marketing all-case surveillance. By February 27, 2022, an independent adjudication committee assessed 138 cases and adjudicated 130 cases as T-DXd-related ILD/pneumonitis. The clinical features and imaging characteristics of these cases were evaluated.

Results

The majority of adjudicated T-DXd-related ILD/pneumonitis cases were grade 1 or 2 (100/

SUBMITTER: Baba T 

PROVIDER: S-EPMC10687185 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature